Please ensure Javascript is enabled for purposes of website accessibility

Why HC2 Holdings Stock Is Surging Today

By Timothy Green - May 2, 2018 at 1:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company has struck a deal to sell a portfolio company for as much as $1 billion.

What happened

Shares of HC2 Holdings (HCHC -3.05%) rocketed higher on Wednesday after the holding company announced that it had struck a deal to sell a portfolio company for as much as $1 billion if all milestones are met. As of 12:50 p.m. EDT, HS2 stock was up 38%.

So what

HC2 announced that BeneVir Biopharm, a portfolio company within its Pansend Life Sciences subsidiary focused on developing oncolytic immunotherapies for cancer treatment, agreed to be acquired by Janssen Biotech. HC2 owns roughly 76% of BeneVir's equity.

A notepad page with a drawing of a big fish eating a little fish.

Image source: Getty Images.

The deal will bring HC2 $140 million in up-front cash payments when it closes, plus additional payments up to $900 million based on certain predetermined milestones. HC2 could ultimately receive more than $1 billion for the company when all is said and done. The deal is expected to close in the second quarter of 2018.

"This transaction is a defining moment for Pansend and HC2, clearly demonstrating David and Cherine's ability to identify and create value in the life sciences industry," said HC2 CEO Philip Falcone, speaking about David Present and Cherine Plumaker, who lead the Pansend subsidiary.

Now what

With a market capitalization of around $230 million as of Tuesday's close, this deal could bring in a tremendous amount of cash relative to the company's value. While there's no guarantee that the full $1 billion of potential payments will be received, investors are clearly thrilled by this news.

Timothy Green has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

HC2 Holdings, Inc. Stock Quote
HC2 Holdings, Inc.
HCHC
$1.59 (-3.05%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
379%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.